Modality
Gene Editing
MOA
KIF18Ai
Target
BTK
Pathway
DDR
Alzheimer'sLN
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
Jan 2022
→ Sep 2031
Phase 1Current
NCT06130148
896 pts·Alzheimer's
2023-04→TBD·Not yet recruiting
NCT03043653
2,217 pts·Alzheimer's
2022-01→2031-09·Completed
3,113 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-025.4y awayInterim· Alzheimer's
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
P1
Not yet…
Catalysts
Interim
2031-09-02 · 5.4y away
Alzheimer's
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06130148 | Phase 1 | Alzheimer's | Not yet recr... | 896 | DOR |
| NCT03043653 | Phase 1 | Alzheimer's | Completed | 2217 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Bemanaritide | Blueprint Medicines | Phase 2 | CD38 |